Abstract
In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15 months. THe beta 2-m appeared to be independent of the level of the paraprotein and its class, as seen in a vertical study of 129 patients. Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2-m production is excessive in advanced disease with or without renal failure. Practical application of the measurement of serum beta 2-m in the stratification and monitoring of patients is suggested.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexanian R., Balcerzak S., Bonnet J. D., Gehan E. A., Haut A., Hewlett J. S., Monto R. W. Prognostic factors in multiple myeloma. Cancer. 1975 Oct;36(4):1192–1201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- Belleville F., Bertrand F., Nabet P. beta2-Microglobuline et gammapathies monoclonales. Pathol Biol (Paris) 1978 Sep;26(6):348–350. [PubMed] [Google Scholar]
- Cresswell P., Springer T., Strominger J. L., Turner M. J., Grey H. M., Kubo R. T. Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A. 1974 May;71(5):2123–2127. doi: 10.1073/pnas.71.5.2123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- DeFronzo R. A., Cooke C. R., Wright J. R., Humphrey R. L. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978 Mar;57(2):151–166. doi: 10.1097/00005792-197803000-00003. [DOI] [PubMed] [Google Scholar]
- Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
- Shuster J., Gold P., Poulik M. D. beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta. 1976 Mar 15;67(3):307–313. doi: 10.1016/0009-8981(76)90339-9. [DOI] [PubMed] [Google Scholar]
- Woodruff R. K., Wadsworth J., Malpas J. S., Tobias J. S. Clinical staging in multiple myeloma. Br J Haematol. 1979 Jun;42(2):199–205. doi: 10.1111/j.1365-2141.1979.tb01124.x. [DOI] [PubMed] [Google Scholar]